Emuaid

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Emuaid
Generic name: SALICYLIC ACID
Manufacturer: Speer Laboratories, LLC
Product type: HUMAN OTC DRUG
SPL set ID: a1486276-30f7-4245-815b-d57edf411cda
SPL ID: e98e1ed5-cef1-462c-ac91-ff1c7bc0d302
Version: 1
Effective date: 2026-01-23
Source export date: 2026-09-28
Source partition: 2
Source file: https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/f7d2b6e3f8600cd856280ab55a9c6fa54a642647191d164f9d1110e89f3f4097/drug-label-0002-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:15:47

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M006	openfda.application_number
brand name		Emuaid	openfda.brand_name
generic name		SALICYLIC ACID	openfda.generic_name
manufacturer name		Speer Laboratories, LLC	openfda.manufacturer_name
ndc	package	55926-0029-1	openfda.package_ndc
ndc	product	55926-0029	openfda.product_ndc
ndc11	package	55926002901	derived:openfda.package_ndc
rxcui		251577	openfda.rxcui
spl id		e98e1ed5-cef1-462c-ac91-ff1c7bc0d302	id
spl set id		a1486276-30f7-4245-815b-d57edf411cda	set_id
unii		O414PZ4LPZ	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings • For external use only • Using other topical acne medication at the same time or immediately following the use of this product pay increase dryness or irritation of the skin • If this occurs, only one medication should be used unless directed by a doctor • Avoid contact with eyes. • If excessive skin irritation develops or increases, discontinue use and consult a doctor.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.